Dolcas unveils high concentration ginger extract

Ginfort can be applied to powder fills, soft gels and liquid capsules. It’s Halal-certified and is in the process of securing Kosher certification

DolCas Biotech has introduced a concentrated all-natural ginger root extract (Zingiber officinale roscoe), branded as Ginfort. The patented bioactive, formulated by Olene Life Sciences in India, carries an approved digestive support claim.

Ginfort’s proprietary extraction process allows Dolcas to achieve low-dose actives with high clinical effectiveness and stability, the company says. Its potency is owed to a blend of food-grade inactives applied to a base material of solvent-free extracts of ginger oleoresins. CO2 is used to isolate and enrich the gingeroids and other ginger actives.

“The unique extraction process for Ginfort optimises the functionality and potency of the oleoresin and other actives in ginger, bringing the millennia-long medicinal uses of ginger to the forefront of science and market development,” said Vivek A. Parachur, co-founder and CEO of Olene.

Gingerol is the most predominant bioactive compound of ginger and is responsible for its characteristic pungent flavor, and the 6-gingerol form is, the most prominent gingeroid. It’s also known for its spasmolytic activity on the gut wall and capacity to normalise gut motility. The phenolic compound is noted for its anti-inflammatory and protective role over gastrointestinal membranes and other tissue types, Dolcas says.

The digestive health-supporting nonvolatile oil components of ginger, gingerols and shogaols, make up less than 3% of fresh ginger. Ginfort’s production process concentrates the highly lipophilic gingeroids to 26% standard and stabilises them in their respective concentrations without compromising on the free-flowing material, the company claims. Of the 26% standard, more than half of it is maintained as 6-gingerol.

“In the fourth quarter of a tumultuous 2020, and at the crossroads of the most festive, food-centered season, we decided to launch Ginfort as DolCas’ newest patented active, bringing our solution for digestive health to people across the globe,” said Dr Shavon Jackson-Michel, Director of Medical and Scientific Affairs.

Ginfort has been evaluated for safety per OECD guidelines, and a study endorsing its beneficial role on dyspepsia is set to be published in the coming months. “This upcoming study on digestive health will be among many studies trials to be performed on Ginfort, as the clinical possibilities are endless,” said K.G.Rao, DolCas President and CEO.

Companies